SCHEMBL3746593

SCHEMBL3746593

CC(C)Cc1cc(C(=O)Nc2nc3ccccc3s2)n(Cc2cccc(C(F)(F)F)c2F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
TP53 P04637 4/20 0.43
CASP3 P42574 3/20 0.42
SENP8 Q96LD8 3/20 0.42
SENP7 Q9BQF6 3/20 0.42
SENP6 Q9GZR1 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
SCD O00767 1/20 0.40
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
LMNA P02545 5/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
KDM4E B2RXH2 2/20 0.40
PTGES O14684 1/20 0.40
TMIGD3 P0DMS9 1/20 0.40
ADORA1 P30542 1/20 0.40
STAT1 P42224 1/20 0.40
NFKB1 P19838 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15104154 0.87 NPC1 (0.40) MAPTTP53CASP3SENP8SENP7
SCHEMBL2661843 0.86 MAPT (0.44) MAPTTP53CASP3SENP8SENP7
SCHEMBL2660234 0.85 MAPT (0.49) MAPTTP53SMN1; SMN2SCDLMNA
SCHEMBL3753585 0.78 CMA1 (0.42) MEN1KMT2AKDM4EALDH1A1
SCHEMBL2660841 0.74 CASP3 (0.49) MAPTTP53CASP3SENP8SENP7
SCHEMBL15104240 0.73 NPC1 (0.41) MAPTTP53CASP3SENP8SENP7
SCHEMBL2661200 0.72 MEN1 (0.45) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL15104416 0.71 CSNK1D (0.47) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL2658577 0.69 GCK (0.41) MAPTTP53LMNA
SCHEMBL2660648 0.68 MEN1 (0.46) MAPTSMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP claimed
US-8299115-B2 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2012-10-30 US claimed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US claimed
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION GCK, PCK1, GCKR MAPT 2927/4885TP53 2638/4885CASP3 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.